Moderna said its cytomegalovirus vaccine failed to meet its goal in a late-stage trial, a setback as it struggles beyond the pandemic https://t.co/dGosyZs0qE ...

Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate any impact to its 2025 financial guidance or its expectation of achieving breakeven in 2028 CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company's investigational cytomegalovi ...

Key Points Moderna's shares have been southbound for the past few years due to unimpressive financial results. However, progress with the pipeline could significantly boost the stock over the next five years. 10 stocks we like better than Moderna › Long gone are the days when Moderna (NASDAQ: MRNA) would generate over $18 billion in annual sales from its COVID-19 vaccine. Over the past couple of years, the company's revenue and earnings have plummeted along with its stock price. Moderna is eager ...

Key Points Moderna may look appealing right now, given the company's high cash balance and extensive drug pipeline. However, as Moderna's cash burn dilemma persists, the company's net value will likely keep declining. For now, it's best to assume that shares will continue to slowly, but steadily, drop in value. 10 stocks we like better than Moderna › Has Moderna (NASDAQ: MRNA) finally bottomed out? You may be asking that yourself right now, as shares in the biotech company have held steady at aro ...

Moderna (MRNA), with its widely used COVID-19 vaccine, rose to prominence during the global pandemic. The stock soared an eye-catching 838.4% between 2020 and 2022. But the company is now stepping into a new era to prove that its mRNA technology can deliver beyond COVID-19. With new vaccine approvals, an expanding pipeline, and ambitious bets on cancer and artificial intelligence, the company is attempting to reinvent itself. But as coronavirus sales fade and competition grows, the question arises whether ...

Core Insights - "Buying the dip" can be risky, especially in defensive sectors like healthcare, where stocks may continue to decline for valid reasons [1] Group 1: Moderna - Moderna transitioned from a biotech start-up to a profitable drug company in 2021 and 2022 due to high demand for its COVID-19 vaccine, Spikevax, generating billions in revenue [2] - Demand for COVID-19 vaccines has significantly decreased, leading to a sharp decline in revenue, with last quarter's total sales at just $142 million [3] - Share prices have fallen approximately 35% year-to-date and around 95% from all-time highs in 2021, with potential for further declines unless positive news is announced in the upcoming earnings report on Nov. 6 [4] Group 2: Novo Nordisk - Novo Nordisk, once a leader in GLP-1 therapies, faces increased competition from companies like Eli Lilly, resulting in a forecasted slowdown in earnings growth for this year and 2026 [5] - Earnings per share are projected to increase by only 3.8% this year and 4.8% in 2026, despite a 22% increase in 2024, with potential negative impacts from governmental pressure on GLP-1 prices [6][8] - Although Novo Nordisk appears cheap with a forward P/E ratio of 14 compared to Eli Lilly's 27, its valuation may not be justified given the growth outlook and potential price pressures [8]

The CNN Money Fear and Greed index showed further easing in the overall fear level, while the index remained in the “Fear” zone on Monday.U.S. stocks settled higher on Monday, with the Dow Jones index gaining more than 500 points during the session, led by a rebound in small-cap stocks and regional banks, easing some of the credit-driven anxiety that shook markets last week. Large-cap benchmarks also posted solid gains.Moderna Inc. (NASDAQ:MRNA) was the top gainer in the S&P 500, jumping around 5%, after an ...

Market Performance Summary - Sinopec Oilfield Service (01033) rose over 12% as the company continues to advance its overseas strategy, with new contract signings increasing by over 70% in the first half of the year [1] - China Hongqiao Group (00931) fell over 13% after a significant 55% surge the previous day, with ongoing discussions regarding potential investments [1] - BYD Electronic (00285) increased over 4% as the company is set to supply power components for NVIDIA's new 800VDC AI server architecture [1] - Horizon Robotics-W (09660) rose over 6% as its HSD technology was first adopted by the ET5 model, with multiple automakers already confirming orders [1] - Bilibili-W (09626) increased over 10% due to strong performance of new games, indicating a gradual release of its commercial value [1] - CRRC Corporation (01766) rose nearly 4% ahead of its third-quarter earnings report, with expectations for continued growth in new train procurement and maintenance [1] - Genscript Biotech (01952) rose over 5% as its EVM14 treatment for squamous cell carcinoma addresses critical clinical needs, leading in clinical development progress [1] - Bosideng (03998) increased nearly 6% following the appointment of renowned British designer Kim Jones as the creative director for its new AREAL high-end urban line [1] - Derin Holdings (01709) fell over 11% after announcing a discounted placement of shares to raise funds for expanding Bitcoin mining operations [1] US Market Highlights - TSMC (TSM.US) rose 0.89% as the first NVIDIA Blackwell wafers were recently produced in the US [3] - Pony.ai (PONY.US) increased 1.76% after partnering with Stellantis for autonomous vehicle solutions [3] - WeRide (WRD.US) rose 2.67% after successfully passing the Hong Kong Stock Exchange hearing, positioning itself to become the first "Robotaxi" stock in Hong Kong [3] - Zeekr (ZK.US) increased 4.48% as pre-sales for the refreshed Zeekr 7X officially began, offering significant pre-sale benefits [3] - iQIYI (IQ.US) rose 8.37% as Morgan Stanley upgraded its target price, citing the long-term growth potential of the domestic IP merchandise market [3] - Taoping (TAOP.US) increased 4.27% after announcing a non-binding letter of intent to acquire 100% of Alphalion Holding Limited [3] - Micron Technology (MU.US) rose 2.17% as several major firms raised their target prices for the company [4] - U.S. Antimony Corporation (UAMY.US) surged 20.02% following its proposal to acquire Larvotto Resources to enhance its critical mineral asset portfolio [4] - Apple (AAPL.US) rose 3.94% as a report indicated strong early sales of the iPhone 17 series in China and the U.S. [4] - Moderna (MRNA.US) increased 4.73% after presenting positive data on its mRNA vaccine pipeline at the IDWeek 2025 conference [4]

智通财经APP获悉，周一，Moderna(MRNA.US)股价走高，截至发稿，该股涨超7%，报27.85美元。消 息面上，Moderna在IDWeek 2025大会上展示其mRNA疫苗管线最新数据，其中包括季节性流感疫苗 mRNA-1010与联合疫苗mRNA-1018的临床结果。数据显示，这两款疫苗在成年受试人群中均能诱发快 速、强效的免疫应答，同时未观察到安全性方面的显著问题。 ...

周一，Moderna(MRNA.US)股价走高，截至发稿，该股涨超7%，报27.85美元。消息面上，Moderna在 IDWeek2025大会上展示其mRNA疫苗管线最新数据，其中包括季节性流感疫苗mRNA-1010与联合疫苗 mRNA-1018的临床结果。数据显示，这两款疫苗在成年受试人群中均能诱发快速、强效的免疫应答， 同时未观察到安全性方面的显著问题。 ...